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ABSTRACT

ARTICLE HISTORY

Introduction: Rapid antiretroviral therapy (ART) initiation can improve patient outcomes such as
viral suppression and prevent new infections. However, not everyone who can start ART does so
immediately.
Methods: We conducted a qualitative study to inform interventions supporting rapid initiation
in the ‘Test and Start’ era. We purposively sampled 20 adult patients living with HIV and a previous gap in care from ten health facilities in Lusaka, Zambia for interviews. We inductively analysed transcripts using a thematic, narrative approach. In their narratives, seven participants
discussed delaying ART initiation.
Results: Drawing on messages gleaned from facility-based counselling and community information, many cited greater fear of rapid sickness or death due to imperfect adherence or treatment
side effects than negative health consequences due to delayed initiation. Participants described
needing time to ‘prepare’ their minds for a lifetime treatment commitment. Concerns about
inadvertent HIV status disclosure during drug collection discouraged immediate initiation, as did
feeling healthy, and worries about the impact of ART initiation on relationship dynamics.
Conclusion: Findings suggest that counselling messages should accurately communicate treatment risks, without perpetuating fear-based narratives about HIV. Identifying and managing
patient-specific concerns and reasons for the ‘need for time’ may be important for supporting
individuals to rapidly accept lifelong treatment.
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KEY MESSAGES
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3.

Fear-based adherence messaging in health facilities about the dangers of missing a treatment dose or changing the time when ART is taken contributes to Zambian patients’
refusals of immediate ART initiation
Responsive health systems that balance a stated need for time to accept one’s diagnosis
and prepare to embark on a lifelong treatment plan with interventions to identify and manage patient-specific treatment related fears and concerns may support more rapid
ART initiation
Perceived social stigma around HIV continues to be a significant challenge for treatment initiation.

Introduction
Despite improved patient outcomes with rapid antiretroviral therapy (ART) initiation [1–4] and widespread
adoption of the World Health Organization’s ‘test and
start’ guideline [5], many people living with HIV delay
CONTACT Chanda Mwamba
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ART initiation [6–11]. A clear understanding of the reasons and factors influencing delayed ART is needed to
inform effective interventions for more rapid initiation
[2,4]. Like many sub-Saharan African countries, Zambia
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adopted the ‘test and start’ strategy in 2016 [12,13].
However, treatment initiation remains sub-optimal [11,14].
Multiple individual, psychosocial, structural, and
health system-related factors are known to influence
ART initiation [15–19]. A systematic literature review
of studies prior to ‘test and start’ in sub-Saharan
Africa, including two studies from Zambia, identified
barriers to ART initiation including fear of stigma, disclosure, and side effects; competing livelihood commitments; structural barriers (e.g. distance and costs);
and clinic-related barriers such as long queues and
poor health care worker (HCW) attitudes [20–24].
Since ‘test and start’ began, four quantitative studies
in Zambia [25–28] and qualitative studies from
Swaziland and Mozambique identified barriers similar
to the pre- ‘test and start’ era, with additions including difficulties accepting diagnosis [29–31]. Most of
the extant literature on ART initiation in Zambia and
the sub-Saharan African region is quantitative.
Among published qualitative studies, only one, from
Tanzania [32], utilises narrative methods. Narrative
research allows for identification of meaning and
sense-making from the perspective of the person
relating the story [33–37]. This patient-centered [38]
perspective is critical to understand and address drivers of delayed ART initiation. Our study sought to
understand reasons for delayed ART start from the
patient perspective and their interpretation of
delayed ART experiences to inform interventions to
optimise treatment outcomes in Zambia.

Methods
Study background and population
Participants were sampled from a larger study that
identified vital status and care outcomes among a
probability sample of adult patients considered lost to
follow-up from HIV care in Zambia [39,40]. Qualitative
interviews were conducted between January and June
2019 with a subset of participants from Lusaka
Province who self-identified as disengaged from care,
but subsequently re-engaged [41]. Out of 65 eligible
participants with telephone contact details in their
medical files, 51 had working telephone numbers.
After 3 call attempts to all 51, we successfully contacted 27, of whom 4 had died, 3 declined, and 20
consented to participate. Among the 20 participants,
seven narrated experiences of delaying ART during
the broader narrative of their HIV care journey. Since
it was not asked about directly, understanding delayed
ART among the subset of participants who raised it as
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a noteworthy component of their HIV care narrative
offers unique and important insight into the behaviour
that can guide intervention development. This paper
presents the results of a secondary data analysis of
the sub-group of participants who discussed delaying
ART initiation in their interviews.

Procedures
Participants were recruited and interviewed in person
by the lead author (CM) following written informed
consent. Interviews were conducted in English, Nyanja
or Bemba, per patient preference and lasted 1–2 h.
Using an individualised guide designed to elicit a
patient’s narrative of care engagement, participants
narrated their experience of their HIV care and treatment journey since their HIV diagnosis. Participants
were not directly questioned about reasons for
delayed ART initiation. The narrative approach allowed
for patient-led sharing of events and contexts associated with delayed ART start, and the meaning
attached to these experiences [33–37].

Analysis
Interview audio recordings were simultaneously translated into English and transcribed verbatim. After each
interview, an analysis memo was created within 24 h
and LB and CM discussed the memos and their meanings. Based on the interview scripts, memos and dialogue, we created chronological narratives of each
patient’s care journey describing contexts and events
that influenced their disengagement, re-engagement
and any subsequent delays with ART initiation. Each
patient summary and transcript was iteratively read in
detail, inductively coded using narrative thematic analysis and categorised into themes [33–37]. Analysis
and interpretation of ART-delay related themes was
restricted to narratives mentioning delayed ART initiation. Analysis was conducted by LB and CM, including dialogue throughout the stages of the
analysis process.

Results
Seven participants from seven health facilities, aged
21–50 years, and all-female but one, described delayed
ART initiation. They were recommended to start ART
and initiated between 2013 and 2017. While the exact
length of treatment delay was not captured, narratives
suggested delays of 3–12 months. Other elements of
patient journeys, including entry into care, time from
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Table 1. Themes and quotes.
Theme
‘If you skip treatment you will die’:
Misconceptions and misinformation

‘I need to think’: Preparing for a
life-long commitment

‘I don’t want people to know my status’:
Concerns about HIV disclosure

‘I was feeling well with my health’:
Difficulty accepting HIV Diagnosis

‘How am I going to manage’:
Concerns about ART consumption

Quote
At the clinic where we were collecting drugs, they were saying that you don’t need to miss taking drugs
and don’t exceed the allocated time for taking drugs, like if you are taking drugs at twenty-one hours
then you take at twenty-three hours, this means that you are creating your own problems, because of
that I was getting scared knowing that sometimes one may forget or one may be busy at the time they
take medicine such that by the time you take the drugs maybe some minutes would have passed, so I
was worried that this will be our death now. [Female, 35–44]
(Friends) said that when you skip the treatment you will die, while others said when you forget to take
them you will die ( … .), so those who have not yet started, they tend to be scared [Female, 55þ]
Okay, what happens when you start then you stop, ( … ) it’s like you’re giving chance to that virus to
come with full force ( … ) And when it comes with full force a lot of illnesses keep coming in. So that’s
what I didn’t want because with me I felt it’s better for me like this without such complications, it will
be better than starting something which I won’t manage to finish by the end of the day. [Male, 25–34]
I said I need to think about it because you know, it’s not something easy whereby you just wake up and
say let me start this. That’s why sometimes you find that people start then they fail to continue or stop.
(Female 34–44)
At first, because I was scared, thinking … how will I start … at which facility will I start from, so you think
of all that, that’s why I was holding back to say I will start taking drugs but needed them (HCWs) to
wait for me first. (Female 18–24)
that issue of screaming [calling out names of people waiting for ART at the clinic] affects me because I
don’t want people to know my status, I don’t want them to know, for me I don’t! maybe I might get
depressed and stop my medicine and that is something I don’t want to do. [Female, 18–24]
I could get embarrassed because if you meet someone you know at the clinic then they could tell
someone they know, they could be talking in the community that we have found such a person
collecting drugs at the clinic, so that is what I was scared of [Female, 35–44]
‘So, when I went there (VCT), I was told, you are HIV positive, then I said hmm how come? I could not
believe it because I was feeling well with my health. Then from there, I went to another clinic to test
again’ [Female 45þ]
R: I didn’t feel good [about diagnosis], and the reason I didn’t feel good is that I looked at my life and
what I went through, how I looked after myself … I had not had multiple partners [Female, 25–34]
You know the way we look at HIV … [made accepting my HIV status] quite challenging, it was something
scary because now I was thinking so I will die soon! Then even when you know the fact that you can’t
die if you take your medication and accept your status and you can live long, there is just always that
fear, it will just pop into your mind. [Female, 25–34 years]
By then, people would talk that the drugs, the tablets are big and then I thought about it, because already
I have a problem taking drugs like Panadol, I usually break it, how about ARVs how am I going to
manage them? [Female, 35–44]
because I’ve seen some side effects from some other people I don’t know, you find that others start
developing a big tummy or maybe the chest is too big ( … .). You can even tell just from the way they
look that they are on treatment. Yes so I was scared of such side effects so to me it was like a gamble
because I didn’t know if I’ll have the same side effects or not. [Female, 25–34]

entry to recommended initation, and disengagement
were varied across the seven participants [42]. Key
themes are described below. Supporting quotes are
summarised in Table 1.

‘If you skip treatment you will die’:
Misconceptions and misinformation
Participants reported receiving counselling messages
that emphasised the importance of perfect adherence,
rather than the overall benefits of treatment. These
post-test messages from HCWs were reinforced
through information heard in participants’ communities. Participants described understanding that delaying treatment was better than starting if they could
not guarantee that they would take ART at the same
time, daily, for a lifetime. They feared that skipping a
dose or stopping for any reason would ‘bring a lot of

illnesses with full force’, likely causing death more
quickly than if they had not initiated.

‘I need to think’: Preparing for a life-long
commitment
When a HCW recommended ART, some participants
explicitly asked to delay immediate start and return
after they had time to ‘prepare’ themselves to commit
to a lifetime of treatment. Preparation was considered
necessary to avoid defaulting. One female participant
‘negotiated’ with the HCW for 3 months before starting ART, stating she needed the time to think about a
‘lot of things’ as starting ART is ‘not something easy
whereby you just wake up and say let me start this.’
Preparation time also involved planning treatment
access, and reflection on dealing with potential unintentional status disclosure.
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‘I don’t want people to know my status’: Concerns
about HIV disclosure
Worries about inadvertent status disclosure and social
consequences of disclosure also discouraged initiation.
Participants cited crowded health facilities and the
ongoing practice of ‘screaming’ out ART patient
names when it was their turn to see a clinician as
threatening disclosure, leading to ‘being gossiped
about’, ‘embarrassment’, ‘shame’, and ‘depression’.
Social relationship dynamics modulated disclosure
fears, with emphasis on how family and friends would
think of them henceforth. One married participant’s
fear of being blamed for infecting her husband with
HIV led her to seek re-testing as a couple
before initiation.

‘I was feeling well with my health’: Difficulty
accepting HIV diagnosis
Many participants described initial difficulty accepting
their HIV diagnosis, and associated fear of HIV and its
consequences, delaying ART start. Participants said
they tested repeatedly at different clinics to verify
results and felt ‘lazy’ to start treatment if they considered themselves ‘healthy’. Having been faithful to a
sexual partner compounded difficulties with status acceptance

‘How am I going to manage’: Concerns about ART
consumption
Concerns about ART, particularly fears of possible side
effects and difficulties swallowing large pills delayed
initiation. Participant fears were heightened by community narratives about ‘big tablets’, hallucinations,
bad dreams, tumours, and body changes. Contrary to
fears before starting ART, multiple participants narrated personal experiences of minimal side effects
post-initiation.

Discussion
We identified factors influencing delayed ART initiation
among adult, Zambian patients with a history of a gap
in HIV care. While adherence remains a key part of the
clinical narrative, we found that fear-based messaging
from HCWs emphasising the consequences of nonadherence are an important factor in delayed initiation. Our finding highlights the need for clear, positive, and nuanced facility-based communications
around ART to assist patients in overcoming feelings
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of fear and assist them in taking decisive steps to initiate life-long treatment.
Given patients’ need for preparation, targeted
improved counselling efforts are likely required to
serve the health system goal of rapid initiation. Better
counselling may include supporting patients to adjust
to initiation of ART then subsequent, follow-ups to
support the readiness needed for sustaining ART longterm; options-based messaging such as contingency
planning for what to do if a dose is missed (e.g. take
immediately, skip until next dose, etc); and/or addressing human resource constraints that limit time and
quality of counselling interactions. Improved
approaches may also help address how patients’ experiences of good health can motivate ART initiation
[15,16,31]. Further, community intervention is needed
to clarify ART requirements and benefits for patients
and their partners [43–45]. Our findings align with
other qualitative studies in the region since the ‘test
and start’ era, which identifies the need by some
patients for time to emotionally process the diagnosis,
come to terms with the new realities of illness and
treatment, and weigh the potential social and individual consequences of being on ART [16,28,46–48].
Given extant literature demonstrating an increased risk
of loss-to-follow-up after same-day ART initiation (2.5
times the likelihood in one Ugandan study) [49], the
identified factors warrant an intentional response to
improve rapid initiation [50–53]. Such approaches may
include patient-centred approaches [54,55] that offer
appropriate follow-up support to retain patients after
ART initiation. Outreach and kindness can facilitate
patient engagement [56]. Our study reinforces the literature that the social complications associated with
disclosure affect myriad HIV-related concerns, including, as shown in our data, delayed initiation of ART
[30]. While there have been consistent efforts targeted
at couples such as HIV couple counselling and testing
[57], there is a need to recognise that HIV initiation is
a socially constructed decision [58] with individuals
weighing their social situations in decisions to initate on
ART. ART programs can address patients’ social circumstances when initiating ART by using patient-centered
communication strategies and tools such as differentiated service delivery (DSD) and community-engagement
to facilitate more rapid initiation [54,59,60].

Study limitations
This study inductively identified themes from seven
patient narratives of HIV care and treatment among
previously disengaged patients. While a small sample
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size, the use of a narrative approach provided rich,
unprompted, information, which reflects participants’
lived experiences. However, the study sample had only
one male, and the study was limited to the capital city,
which is more urban and wealthier than other areas.
Therefore, the study may not have identified the full
breadth of reasons for the delay for these other categories. Our sample included all willing participants among
patients from the probability-based sample of the parent study who returned to HIV care in Lusaka. The proportion recounting delay was consistent with regional
estimates of treatment refusal [17,41].
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Conclusion
Health providers in the ‘test and start’ era must be
aware of misperceptions and a “fear narrative” about
HIV, its treatment demands, and side effects. It is
important then that the facility messaging addresses
these fears to reassure patients while giving them
comprehensive and accurate information about the
benefits and realities of ART. Consistency in reasons
for delayed ART initiation across settings warrants a
dedicated response to reduce time to initiation.
Interventions to appropriately support patients’ need
for time while building individual judgement and
agency of HIV care, social and health system resilience
may shorten their time to initiation.
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